Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Melasma: later-stage trial registry

2 of 9 indexed Melasma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Melasma: 9 US clinical trials tracked, 2 recruiting.

Melasma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Sadick Research Group, running 1 of these trials.

Enrollment posture brief

Registry condition melasma

OPEN 2 | RECR 22% | LATE 2 | EARLY 1 | RANK #1916 | SPON 1

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Melasma (this)22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Melasma

Melasma lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Melasma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Melasma is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Melasma trials is spread across many organizations.

    Sadick Research Group accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Melasma trials plan to enrol fewer than 100 people.

    Median target enrolment is 20 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.

  4. Melasma research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 42

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 4 2

Named interventions

Most-linked intervention names on Melasma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hydroquinone skin care regimen Other
1 trials
Revlite Laser System with hydroquinone skin care regimen Device
1 trials
Hydroquinone Drug
1 trials
Herbal depigmenting agent (Epionce) Other
1 trials
SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen Other
1 trials
SkinMedica Rejuvenative Moisturizer Other
1 trials
SkinMedica Facial Cleanser Other
1 trials
4% Hydroquinone Topical Cream Drug
1 trials

US sites by state

Facility locations filed on Melasma trials. A trial with sites in several states counts in each.

New York 4 trials
Texas 2 trials
California 2 trials
New Jersey 1 trials
North Carolina 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Melasma page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melasma condition card totals 9 registered trials; most-linked intervention Hydroquinone skin care regimen; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.